Details of the SBP
| General Information of Synthetic Binding Protein (SBP) (ID: SBP000142) | ||||||
|---|---|---|---|---|---|---|
| SBP Name |
BiTE Pasotuxizumab
|
|||||
| Synonyms |
AMG-212; AMG212; BAY 2010112; MT-112
|
|||||
| Design Method | Traditional methods (Site-directed mutagenesis and/or Directed evolution) | |||||
| Highest Status | Phase I | |||||
| Protein Scaffold Information of This SBP | ||||||
|---|---|---|---|---|---|---|
| Scaffold ID | PS018 | [1] , [2] | ||||
| Scaffold Name | BiTE | |||||
| Scaffold Class | Antibody fragment | |||||
| Fold Type | Beta-Sheets + Loops | |||||
| Binding Target(s) of This SBP (BTS) |
|---|
| BTS Name | Details | Mechanism | Application | Affinity | Research Organization | Ref |
|---|---|---|---|---|---|---|
| T-cell surface glycoprotein CD3 | Binder | Metastatic castration-resistant prostate cancer [ICD-11: 2C82.Y] | N.A. | Bayer; Amgen | [1] , [2] | |
| Glutamate carboxypeptidase 2 | Binder | Metastatic castration-resistant prostate cancer [ICD-11: 2C82.Y] | N.A. | Bayer; Amgen | [1] , [2] | |
| Clinical Trial Information of This SBP | ||||||
|---|---|---|---|---|---|---|
| NCT01723475 | Click to show the Detail | |||||
| Indication | Castration-Resistant Prostate Cancer (CRPC) | |||||
| Phase | Phase I | |||||
| Title | An Open-label, Phase I, Dose-escalation Study to Characterize the Safety, Tolerability, Pharmacokinetics, and Maximum Tolerated Dose of?BAY 2010112, Given Once Daily by Subcutaneous Administration or by Continuous Intravenous Infusion, in Subjects With Castration-resistant Prostate Cancer | |||||
| Status | Completed | |||||
| Sponsor | Bayer | |||||